The effects of GLP-1 analogues, DPP-4 inhibitors and SGLT2 inhibitors on the renal system.
Bottom Line: Optimal treatment and prevention of DN may require an early, intensive, multifactorial approach, tailored to simultaneously target all modifiable risk factors.Dipeptidyl peptidase (DPP)-4 inhibitors and sodium-glucose cotransporter 2 (SGLT2) inhibitors lower blood glucose levels without additional risk of hypoglycaemia, and may also reduce albuminuria.Further investigation of the potential renal benefits of DPP-4 and SGLT2 inhibitors is underway.
Affiliation: Department of Medicine I, Rudolfstiftung Hospital, Vienna, Austria firstname.lastname@example.org.Show MeSH
Related in: MedlinePlus
License 1 - License 2 - License 3
Mentions: Incretin-based therapies for the treatment of hyperglycaemia include the injectable GLP-1 receptor agonists and the orally active DPP-4 inhibitors, both of which stimulate insulin secretion and inhibit glucagon secretion in a glucose-dependent manner. Among the substrates of DPP-4 are peptide hormones such as B-type natriuretic peptides, neuropeptide Y, peptide YY and stromal cell-derived factor-1α (Figure 2),62,63 which are thought to be responsible for the cardio-renal effects potentially beneficial for patients with T2DM.63,64
Affiliation: Department of Medicine I, Rudolfstiftung Hospital, Vienna, Austria email@example.com.